220 related articles for article (PubMed ID: 18083135)
1. Serum tumor marker CA19-9 in the follow-up of patients with cystic echinococcosis.
Yuksel BC; Yildiz Y; Ozturk B; Berkem H; Katman U; Ozel H; Hengirmen S
Am J Surg; 2008 Apr; 195(4):452-6. PubMed ID: 18083135
[TBL] [Abstract][Full Text] [Related]
2. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
4. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
5. Measurement of tumor markers in chronic hemodialysis patients.
Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
[TBL] [Abstract][Full Text] [Related]
6. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
8. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9.
Gao YC; Yuan ZB; Yang YD; Lu HK
Scand J Clin Lab Invest; 2007; 67(7):741-7. PubMed ID: 17852813
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters.
Christoforidis A; Lefkou E; Vlachaki E; Perifanis V; Tsatra I; Dogramatzi F; Athanassiou-Metaxa M
Ann Hematol; 2007 Nov; 86(11):837-41. PubMed ID: 17668208
[TBL] [Abstract][Full Text] [Related]
10. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
[TBL] [Abstract][Full Text] [Related]
11. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
13. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
15. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
16. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of tumor markers in gestational trophoblastic diseases.
Ahmad AE; Dehaghani AS; Shaker M; Fattahi MJ
J Reprod Med; 2008 Dec; 53(12):930-4. PubMed ID: 19160651
[TBL] [Abstract][Full Text] [Related]
18. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
[No Abstract] [Full Text] [Related]
19. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
20. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
Yang XQ; Yan L; Chen C; Hou JX; Li Y
Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
